Breaking News Headlines Today | Ground News

See every side of every news story

Deutsches Ärzteblatt image

News from Deutsches Ärzteblatt

Ground News rates Deutsches Ärzteblatt’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Deutsches Ärzteblatt’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Deutsches Ärzteblatt

Where is Deutsches Ärzteblatt located?Deutsches Ärzteblatt's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Deutsches Ärzteblatt News

Ebola Cases in Congo Rise as Authorities Race to Contain Spread of Outbreak, Health Agency Says — REUTERS / pwu404

Ebola · Democratic Republic of the Congo

Ebola Cases in Congo Rise as Authorities Race to Contain Spread of Outbreak, Health Agency Says

58% Center coverage: 59 sources

Towns affected by Congo's latest Ebola outbreak have erected checkpoints to restrict population movements, officials said this week, as cases increased slightly and aid workers warned that the response was underfunded. See the Story

For the first time, more of the world’s children are now obese than underweight: UNICEF — REUTERS / ixx511

Obesity · Geneva

For the first time, more of the world’s children are now obese than underweight: UNICEF

40% Center coverage: 50 sources

Higher-Dose Semaglutide Injection Proves Mettle in Phase III Trials

Higher-Dose Semaglutide Injection Proves Mettle in Phase III Trials

60% Left coverage: 5 sources

(MedPage Today) -- Tripling the weekly dose of semaglutide (Ozempic, Wegovy) resulted in greater weight loss compared with placebo in adults with obesity, both with and without type 2 diabetes, but did not increase the risk of serious adverse events...See the Story

Breaking News Topics Related to Deutsches Ärzteblatt